DREAMS-3 is the first multinational, head-to-head Phase 3 trial of a GCG/GLP-1 dual agonist against semaglutide in diabetes care, marking a major advance in next-generation metabolic therapeutics
Glycine and cysteine (commonly provided as N-acetylcysteine, or NAC) are amino acids
No approved obesity therapy directly activates the glucagon receptor
However, the use of reliable and robust mathematical models with predictive capabilities, known as the quantitative pharmacology approach (QP-A) and model-based drug development (MBDD), holds promise as a supportive strategy
Amino Acids (this issue) Li L, Hsu A, Moore PK (2009) Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulfide in the cardiovascular system and in inflammationa tale of three gases